Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results

Keywords

Alzheimer Disease ×

Show more Keywords

Select data models

Selected data models

You must log in to select data models for download or further analysis.

186 Search results.

Eligibility Atypical Alzheimers Disease NCT01723553

- 8/15/19 - 1 form, 2 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

REFLECT-1 Serious Adverse Events NCT00428090

- 4/23/19 - 1 form, 7 itemgroups, 18 items, 1 language

Itemgroups: Serious Adverse Event (SAE), Serious Adverse Event: Seriousness, Ongoing Event, Medical Condition, Concomitant Medication, Assessment, Identification and Signature

NCT00428090 / GSK-AVA105640 A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1) A serious adverse event is any untoward medical occurence taht, at any dose: a) results in death. b) is life-threatening. Note: The term "life-threatening" in the definition of "serious" refers to an event in which the subject was at risk of death at the time of the event. It dies not refer to an event, which hypothetically might have caused death, if it were more severe. c) requires hospitalisation or prolongation of existing hospitalisation. Note: In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight stay9 at the hospital or emergency ward fro observation and/or treatment that would not have been appropriate in the physicican's office or out-patient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hopsialisation or fulfills any other serious criteria, the event is "serious". When in doubt as to whether "hospitalisation" occured or was necessary, the AE should be considered "serious". Hospitalisation for elective treatment of pre-existing condition that did not worsen from baseline is not considered an AE. d) results in disability/incapacity, or Note: the term disability means a sbustantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not consitute a substantial disruption. e) is a congenital anomaly/birht defect. f) other. Medical or scientific judgement should be exercised in deiding whether reporting is appropriate in other situations, such as important medical events that may not be immedaitely life-threatening or result in death or hospitalisation but may jeopardise the subejct or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convusions that do not result in hospitalisation, or development of drug dependency or drug abuse.

Eligibility Genetic Risk for Alzheimer's Disease NCT02087865

- 3/31/19 - 1 form, 2 itemgroups, 12 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02087865

Study of Alzheimer's Disease in Down Syndrome NCT02141971 - Eligibility

- 3/26/19 - 1 form, 2 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Non-randomized natural history study involving 12 subjects with Down Syndrome, who are aged 30-60 years old. This study will observe 3 different groups: four non-demented subjects between ages 30-40 years old, four non-demented subjects between ages 40-50 years old, and four demented subjects 50-60 years old. ODM derived from: https://clinicaltrials.gov/show/NCT02141971

Eligibility Mild Cognitive Impairment NCT02353884

- 1/17/19 - 1 form, 2 itemgroups, 10 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion; ODM derived from: https://clinicaltrials.gov/show/NCT02353884

Eligibility Behavioral and Psychological Symptoms in Alzheimer's Disease NCT02103673

- 12/6/18 - 1 form, 2 itemgroups, 8 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia; ODM derived from: https://clinicaltrials.gov/show/NCT02103673

Eligibility Memory Disorders NCT00938665

- 9/26/18 - 1 form, 4 itemgroups, 33 items, 1 language

Itemgroups: Inclusion Criteria AD Cohort, Inclusion criteria normal control, Exclusion Criteria AD Cohort, Exclusion criteria normal control

Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.; ODM derived from: https://clinicaltrials.gov/show/NCT00938665

Eligibility Memory Complaint NCT02062099

- 9/24/18 - 1 form, 4 itemgroups, 11 items, 1 language

Itemgroups: Common inclusion Criteria, Inclusion criteria for mild to moderate Alzheimer's, Inclusion criteria for amnestic mci patients, Inclusion criteria for patients with isolated memory complaint

PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO); ODM derived from: https://clinicaltrials.gov/show/NCT02062099